Hematologic Oncology

Comprehensive insight on the signs and symptoms that help lead to the identification of tumor lysis syndrome in patients receiving therapy for cancer.

Key opinion leaders James Short, MD, and John Reagan, MD, share an overview on the incidence and clinical risk factors of tumor lysis syndrome.

Amer Zeidan, MBBS, and Rami Komrokji, MD, compare the available IPSS-M and IPSS-R tools for stratifying risk and assessing prognosis in MDS.

Distinguished experts in hematology discuss the WHO and ICC classification systems for myelodysplastic syndromes (MDS), including recent WHO updates.

The FDA has granted an orphan drug designation to JBI-802 for the treatment of patients with small cell lung cancer and acute myeloid leukemia.

Axicabtagene ciloleucel continued to elicit improved progression-free survival and overall response rates in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Patients with B-cell malignancies who were intolerant to acalabrutinib experienced a longer treatment duration when subsequently receiving zanubrutinib.

In this first episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, provides perspective on the use of daratumumab-based quadruplets as induction therapy in multiple myeloma.

Emma Searle, PhD, provides an overview of findings from the MajesTEC-2 trial in patients with relapsed/refractory multiple myeloma, elaborates on the safety of teclistamab plus daratumumab and lenalidomide, and discusses the next steps for evaluating the combination.

Moxetumomab pasudotox-tdfk will be permanently discontinued in the United States market for the treatment of relapsed/refractory hairy cell leukemia.

A brief review of the different regimens used by experts for GvHD prevention at their institutions and discuss the importance of GvHD Prevention.

Expert oncologists define graft vs host disease (GvHD) and discuss which risk factors might increase a patient’s risk of developing GvHD.

Closing out their discussion on the management of myelofibrosis, panelists highlight updated data with fedratinib and ruxolitinib, respectively.

Pau Montesinos, MD discusses key updates from the global phase 3 AGILE study, as presented at the 2022 American Society of Hematology Annual Meeting, and speaks to the clinical implications of these data.

A brief review of the biology of myelofibrosis, the potential for disease modification, and subsequent implications for treatment.

The European Commission has issued an orphan drug designation to duvelisib for the treatment of adult patients with peripheral T-cell lymphoma.

Chan Y. Cheah, MD, MBBS, discusses the the phase 1 BGB-11417-101 trial, which showed that the BCL-2 inhibitor BGB-11417, administered alone or in combination with the BTK inhibitor zanubrutinib, induced promising response rates and was well tolerated patients with chronic lymphocytic leukemia.

Japan’s Ministry of Health, Labor, and Welfare has approved acalabrutinib for the treatment of previously untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

The FDA has accepted a biologics license application for glofitamab for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy.

Key opinion leaders on myeloproliferative neoplasms review clinical data behind pacritinib therapy in the setting of myelofibrosis.

Switching their focus to myelofibrosis management, expert panelists reflect on clinical data behind momelotinib, a novel JAK2 inhibitor.

Joseph Alvarnas, MD, discusses the importance of access to CAR T-cell therapy in cancer care.

Sanjeet Singh Dadwal, MD, discusses the investigation of posoleucel as a prevention strategy for infections in patients following an allogenic hematopoietic cell transplant.

Johannes Zakrzewski, MD, discusses the investigation of a nanoframework-based delivery system for IT848 in hematologic malignancies.

Max S. Topp, MD, highlights the rationale for studying bispecific antibodies in newly diagnosed diffuse large B-cell lymphoma, how the safety profile of glofitamab plus R-CHOP contributes to its potential for outpatient administration, and where future directions with this research may lead.